A Salivary Urea Nitrogen Dipstick to Detect Obstetric-Related Acute Kidney Disease in Malawi

listen audio

Study Justification:
– Obstetric-related acute kidney injury (AKI) is a significant issue in low-income countries and can have adverse outcomes for both mother and fetus.
– Current diagnostic tools for obstetric-related AKI are limited, and there is a need for laboratory-independent tools to facilitate diagnosis.
– This study aimed to assess the diagnostic performance of a salivary urea nitrogen (SUN) dipstick in detecting obstetric-related AKI in Malawi.
Study Highlights:
– The study was conducted at Queen Elizabeth Central Hospital in Blantyre, Malawi, which provides obstetric and nephrology care to the southern region of Malawi.
– A total of 301 high-risk women were included in the study, with 7.6% of them diagnosed with AKI.
– The SUN dipstick showed specificity but low sensitivity in diagnosing obstetric-related AKI.
– Limited biochemical derangement and low salivary urea concentrations in pregnancy may have contributed to the lack of sensitivity.
Study Recommendations:
– Further research is needed to explore alternative diagnostic tools for obstetric-related AKI in low-income countries.
– Future studies should investigate the reasons for limited sensitivity of the SUN dipstick and explore potential modifications to improve its diagnostic performance.
Key Role Players:
– Obstetricians and gynecologists
– Nephrologists
– Laboratory technicians
– Researchers and scientists
– Policy makers and government officials
Cost Items for Planning Recommendations:
– Research funding for further studies and development of alternative diagnostic tools
– Salivary urea nitrogen dipstick production and distribution
– Training and education for healthcare professionals on the use of new diagnostic tools
– Infrastructure and equipment for laboratories and testing facilities
– Data collection and analysis
– Publication and dissemination of research findings

The strength of evidence for this abstract is 6 out of 10.
The evidence in the abstract is rated 6 because the study conducted was a prospective observational study with a relatively small sample size. The diagnostic performance of the salivary urea nitrogen (SUN) dipstick to detect obstetric-related acute kidney disease was assessed, but the sensitivity was found to be low. The study acknowledges that the lack of sensitivity may be due to limited biochemical derangement and low salivary urea concentrations in pregnancy, rather than a technical limitation of the dipstick itself. To improve the evidence, future studies could consider increasing the sample size, including a more diverse population, and exploring other potential biomarkers for diagnosing obstetric-related acute kidney disease.

Introduction: Obstetric-related acute kidney injury (AKI) is associated with adverse outcomes for mother and fetus, particularly in low-income countries. However, laboratory-independent tools to facilitate diagnosis are lacking. We assessed the diagnostic performance of a salivary urea nitrogen (SUN) dipstick to detect obstetric-related acute kidney disease in Malawi. Methods: Women at high risk for AKI admitted to an obstetric unit in Blantyre, Malawi, were recruited between 21 September and 11 December 2015. Patients underwent serum creatinine (SCr) testing alongside measurement of SUN using a dipstick on admission, and every 48 hours thereafter if evidence of kidney disease was found. Results: A total of 301 patients were included (mean age 25.9 years, 11% HIV positive). Of the patients, 23 (7.6%) had AKI, stage 1 in 47.8%, most commonly due to preeclampsia/eclampsia. Mean presenting SCr values were 108.8 ± 21.8 μmol/l (1.23 ± 0.25 mg/dl), 118 ± 34.45 μmol/l (1.33 ± 0.39 mg/dl), and 136.1 ± 30.4 μmol/l (1.54 ± 0.34 mg/dl) in AKI stages 1 to 3 respectively. SUN > 14 mg/dl had a sensitivity of 12.82% and a specificity of 97.33% to detect acute kidney disease; the area under the receiver operating characteristic curve was 0.551. In patients with normal SUN on admission, perinatal mortality was 11.8%, and was 25.0% if SUN was?> 14 mg/dl (P = 0.18). Conclusion: The SUN dipstick was specific but insensitive when used to diagnose obstetric-related AKI. Limited biochemical derangement and low salivary urea concentrations due to physiological changes in pregnancy, as opposed to a technical limitation of the dipstick itself, are the likely reason for the lack of sensitivity in this study.

We conducted a prospective observational study at Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi. This hospital acts as a district hospital for Blantyre and also provides tertiary obstetric and nephrology care to the southern region of Malawi. The majority of obstetric admissions are from Blantyre district, encompassing both urban and rural populations, and the obstetric unit delivers approximately 12,000 babies per year. Despite its being ranked as one of the poorest countries worldwide, health care in Malawi is government funded and provided to all free at the point of delivery. At QECH, this includes access to a high-dependency obstetric unit and hemodialysis for AKI. We included women admitted to QECH obstetric department who were > 20 weeks’ gestation or  82μmol/l was considered to be elevated, predefined as 2 SDs above the mean in the third trimester of pregnancy.15 Patients with elevated SCr were managed jointly by the obstetric and nephrology teams, and the nature (as per definitions below) and cause of kidney injury were determined. The women underwent daily measurement of SCr and urine output, and further measurement of SUN dipstick and serum urea at 48 hours. The obstetric team alone managed patients without raised SCr on admission. Patients and neonates were followed up until hospital discharge. Maternal and fetal outcomes (gestational age at delivery, birth weight, first Apgar score,16 in-hospital maternal and perinatal mortality) were recorded in the entire study population. After a period of 15 minutes without eating or drinking, patients provided unstimulated saliva into a plastic cup, and a 50-μl quantity was used to moisten the test pad of a colorimetric SUN dipstick. The change in color of the test pad was assessed at 1 minute and compared to 6 reference pads corresponding to increasing SUN concentrations: 5 to 14 mg/dl (pad 1), 15 to 24 mg/dl (pad 2), 25 to 34 mg/dl (pad 3), 35 to 54 mg/dl (pad 4), 55 to 74 mg/dl (pad 5), and ≥ 75 mg/dl (pad 6) (Supplementary Figure S1). During analysis, SUN was transformed to a continuous variable by converting the test pad result to the midpoint for each range (e.g., a SUN result of 5−14 mg/dl was transformed to 9.5 mg/dl). SCr and urea were measured by the Jaffe and urease methods, respectively, using either a Flexor Junior Clinical Chemistry Analyzer (Vital Scientific, Dieren, Netherlands) or a Mindray Chemistry Analyzer BS-120 (Shenzen Mindray Bio-Medical Electronics Company, Shenzen, China) in a local laboratory. Analyzers were calibrated in accordance with the manufacturer’s instructions. AKI and CKD were defined and staged by Kidney Disease Improving Global Outcomes (KDIGO) criteria.17, 18 Patients with elevated SCr (>82 μmol/l) on admission that did not fulfill KDIGO criteria for AKI or CKD were defined, by our own definition, as having acute kidney disease (AKD) without AKI. Any acute kidney disease encompassed both AKI and AKD without AKI. Patients with normal SCr on admission were deemed as having no kidney disease (NKD) (Supplementary Table S2). The nephrology study team determined the primary cause of AKI. Perinatal mortality was defined as fetal death after 20 weeks’ gestation (stillbirth or termination of pregnancy) or in-hospital neonatal death. The primary outcome was the diagnostic performance of the SUN dipstick to detect obstetric-related acute kidney disease (AKI and AKD without AKI). Secondary outcomes were comparison of SUN concentrations in those with and without AKI, and assessment of maternal and perinatal in-hospital outcomes (gestational age, birth weight, first Apgar score, maternal and perinatal mortality) according to the presence of AKI and SUN results. Descriptive data are presented as mean ± SD and as median ± interquartile range (IQR), depending on the distribution of data and the standard parametric and nonparametric tests used. Diagnostic performance of SUN was determined by sensitivity and specificity, and by the area under the receiver operating characteristic (ROC) curve. The optimal threshold of SUN to diagnose kidney disease was calculated according to the Youden Index. Statistical analysis was performed using Graphpad Prism version 7 (www.graphpad.com). A P value of < 0.05 was considered statistically significant.

One potential innovation to improve access to maternal health is the development of a salivary urea nitrogen (SUN) dipstick to detect obstetric-related acute kidney disease. This innovation was assessed in a study conducted in Malawi, where laboratory-independent tools for diagnosing acute kidney injury (AKI) are lacking. The study found that the SUN dipstick was specific but insensitive in diagnosing obstetric-related AKI. The dipstick had a sensitivity of 12.82% and a specificity of 97.33% to detect acute kidney disease. The study also found that perinatal mortality was higher in patients with elevated SUN levels. However, the lack of sensitivity may be due to limited biochemical derangement and low salivary urea concentrations in pregnancy, rather than a technical limitation of the dipstick itself. Further research and development may be needed to improve the sensitivity of the SUN dipstick for diagnosing obstetric-related AKI.
AI Innovations Description
The recommendation to improve access to maternal health is the development and implementation of a salivary urea nitrogen (SUN) dipstick to detect obstetric-related acute kidney disease in Malawi. This recommendation is based on a prospective observational study conducted at Queen Elizabeth Central Hospital in Blantyre, Malawi.

The study aimed to address the lack of laboratory-independent tools for diagnosing obstetric-related acute kidney injury (AKI) in low-income countries. The researchers assessed the diagnostic performance of a SUN dipstick in detecting obstetric-related acute kidney disease.

A total of 301 patients at high risk for AKI were included in the study. The results showed that the SUN dipstick had a specificity of 97.33% but a low sensitivity of 12.82% in detecting acute kidney disease. The area under the receiver operating characteristic curve was 0.551.

The study concluded that the SUN dipstick was specific but insensitive in diagnosing obstetric-related AKI. The lack of sensitivity was attributed to limited biochemical derangement and low salivary urea concentrations due to physiological changes in pregnancy, rather than a technical limitation of the dipstick itself.

Implementing the use of a SUN dipstick could potentially improve access to maternal health by providing a simple and cost-effective tool for diagnosing obstetric-related acute kidney disease. However, further research and development may be needed to improve the sensitivity of the dipstick in detecting kidney disease in pregnant women.
AI Innovations Methodology
The study mentioned in the description focuses on the use of a salivary urea nitrogen (SUN) dipstick to detect obstetric-related acute kidney disease in Malawi. This innovation aims to provide a laboratory-independent tool for diagnosing kidney disease in pregnant women, particularly in low-income countries where access to healthcare resources may be limited.

To simulate the impact of this recommendation on improving access to maternal health, a methodology could be developed as follows:

1. Study Design: Conduct a prospective observational study at selected healthcare facilities in Malawi, similar to the study conducted at Queen Elizabeth Central Hospital (QECH) in Blantyre. This would involve recruiting women at high risk for acute kidney disease and collecting relevant clinical data.

2. Participant Selection: Include women who are at least 20 weeks pregnant or within 6 weeks postpartum and present with conditions known to be at risk of leading to acute kidney injury. This could include gestational hypertension, preeclampsia, eclampsia, antepartum hemorrhage, postpartum hemorrhage, sepsis, renal failure, and heart failure.

3. Informed Consent: Ensure that all participants provide written informed consent to participate in the study. Obtain ethical approval from the relevant research ethics committee.

4. Baseline Data Collection: Record baseline clinical data for each participant, including relevant medical history, gestational age, and presenting symptoms.

5. Diagnostic Testing: Use the SUN dipstick to measure salivary urea nitrogen levels in addition to serum creatinine testing. Perform these measurements on admission and at regular intervals thereafter if evidence of kidney disease is found.

6. Follow-Up and Monitoring: Monitor participants closely during their hospital stay, recording daily measurements of serum creatinine, urine output, and additional SUN dipstick measurements. Assess maternal and fetal outcomes, including gestational age at delivery, birth weight, first Apgar score, and in-hospital maternal and perinatal mortality.

7. Data Analysis: Analyze the collected data using appropriate statistical methods. Calculate the sensitivity, specificity, and area under the receiver operating characteristic curve to evaluate the diagnostic performance of the SUN dipstick. Compare SUN concentrations in participants with and without acute kidney disease. Assess maternal and perinatal outcomes based on the presence of kidney disease and SUN results.

8. Statistical Significance: Determine statistical significance using appropriate tests, such as parametric and nonparametric tests, and consider a significance level of less than 0.05.

By following this methodology, researchers can simulate the impact of using the SUN dipstick to improve access to maternal health by providing a non-invasive and cost-effective tool for diagnosing obstetric-related acute kidney disease. The results of the study can then be used to inform healthcare policies and interventions aimed at improving maternal health outcomes in low-income countries like Malawi.

Yabelana ngalokhu:
Facebook
Twitter
LinkedIn
WhatsApp
Email